|Articles|January 18, 2002
New CBER Guidance, Posted 9 January 2002
Author(s)BioPharm International Editors
Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
2025 PharmSci 360 to Showcase Essential AI Integration and Emerging Technologies
2
Top 10 Questions from CPHI Frankfurt: Building Pharma Resilience a Common Theme
3
Pharma Tariff FAQ: Costs, Supply Chains, Policy for 2025
4
Meeting Global Demand and Delivering Faster, More Reliable Service
5
